CSIMarket Company Name, Ticker, Competitors, else..
 
Bellicum Pharmaceuticals Inc   (BLCM)
Other Ticker:  
 
 
Price: $0.0748 $-0.01 -6.617%
Day's High: $0.09 Week Perf: -7.65 %
Day's Low: $ 0.07 30 Day Perf: -6.5 %
Volume (M): 6 52 Wk High: $ 0.29
Volume (M$): $ 0 52 Wk Avg: $0.14
Open: $0.08 52 Wk Low: $0.06



 Market Capitalization (Millions $) 2
 Shares Outstanding (Millions) 31
 Employees -
 Revenues (TTM) (Millions $) 1
 Net Income (TTM) (Millions $) 3
 Cash Flow (TTM) (Millions $) -23
 Capital Exp. (TTM) (Millions $) 0

Bellicum Pharmaceuticals Inc
Bellicum Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing cell therapies for various types of cancers and other serious diseases. The company utilizes its proprietary Controlled Switch Technology (CST) platform to engineer and control cellular therapies. Bellicum's CST platform allows for the activation and elimination of these cellular therapies to enhance safety and efficacy.

The company's lead product candidate, BPX-601, is a CAR-T cell therapy that is being developed for the treatment of pancreatic cancer. Bellicum also has a pipeline of other product candidates in various stages of development, targeting different types of cancers, including prostate and ovarian cancer.

In addition to cancer, Bellicum is exploring the potential of its CST platform for other therapeutic areas such as inherited blood disorders and autoimmune diseases. The company has collaborations with eminent research institutions and pharmaceutical companies to advance its technology and develop innovative treatments.

Bellicum Pharmaceuticals Inc is dedicated to improving patient outcomes through its cell therapy platform and continues to invest in research and development to bring new and effective treatments to market.


   Company Address: 3730 Kirby Drive, Houston, 77098 TX
   Company Phone Number: 454-3424   Stock Exchange / Ticker: BLCM


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals Inc. Surpasses Expectations with Strong Third Quarter Performance


Date: September 30, 2023
Bellicum Pharmaceuticals Inc has delivered a promising performance during the fiscal span of July to September 2023, as reflected in their recent financial results. The company reported a significant decrease in loss per share compared to the previous year, with a loss of $-0.02 per share compared to $-0.23. Moreover, earnings per share (EPS) improved from $-0.24 per share in the previous reporting period.
Despite a slight decline in revenue by 0.89%, totaling $1.00 million compared to $1.01 million in the corresponding quarter last year, Bellicum Pharmaceuticals has showcased a resilient stance. Additionally, sequential revenue from the previous period was maintained at $0.00 million.
Bellicum Pharmaceuticals Inc

BLCM's Fiscal Second Quarter of 2023 Reveals Alarming Increase in Deficit Compared to Previous Year

Bellicum Pharmaceuticals Inc, a biopharmaceutical company specializing in developing novel cellular immunotherapies for various cancers and orphan inherited blood disorders, recently released its second-quarter financial report for 2023. Unfortunately, the report painted a grim picture for the company, with revenues dwindling down to $0.00 million, marking a significant decline from the corresponding quarter the previous year.
The net deficit per share also saw a substantial increase, surging to -$0.24 from -$0.26 per share in the previous quarter. Additionally, the fiscal second quarter of 2023 saw Bellicum Pharmaceuticals Inc experience a net shortfall of -$7.352 million, which is more significant compared to the -$4.001 million shortfall reported a year ago.
Bellicum Pharmaceuticals Inc

Bellicum Pharmaceuticals Inc Faces Drastic Decline in Revenue as First Quarter 2023 Earnings Season Unveils

Bellicum Pharmaceuticals Inc reports a concerning decrease in revenue and an increase in shortfall per share for the financial interval ending on March 31, 2023. The company's revenue dropped by -7.143% to $0.01 million compared to the previous reporting period, while the shortfall per share has increased to $-0.26 per share.
This decrease in revenue can be attributed to a lower demand for the company's products. Due to this lower demand, the company has faced a greater shortfall, resulting in a net shortfall of $-8.066 million for the financial interval closing on March 31, 2023. This shortfall is larger than the previous year's net shortfall of $-7.562 million.
These figures represent a major concern for Bellicum Pharmaceuticals Inc and its investors. Such a decline in revenue and an increase in shortfall per share can indicate that the company may be struggling to remain financially stable or to generate profits. It is vital for the company to address these issues and take measures to bolster its financial stability.






Bellicum Pharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com